| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Through the A2B receptor, adenosine-2'-monophosphate (2'-AMP) (0-100 µM; once daily for 4 days) suppresses the proliferation of glomerular mesangial cells and preglomerular vascular smooth muscle cells [1]. In primary mouse microglia, LPS-induced (100 ng/ml) TNF-α and CXCL10 production is inhibited by adenosine 2'-monophosphate (30 μM; 24 hours) [1].
|
|---|---|
| References |
|
| Additional Infomation |
Adenosine 2'-phosphate is a purine ribonucleoside 2'-monophosphate. It has a role as a Saccharomyces cerevisiae metabolite. It is a conjugate acid of an adenosine 2'-phosphate(2-).
2'-Adenylic acid has been reported in Aeromonas veronii with data available. Adenosine 2'-phosphate is a metabolite found in or produced by Saccharomyces cerevisiae. Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. |
| Molecular Formula |
C10H14N5O7P
|
|---|---|
| Molecular Weight |
347.22
|
| Exact Mass |
347.063
|
| CAS # |
130-49-4
|
| PubChem CID |
94136
|
| Appearance |
White to off-white solid powder
|
| Density |
2.3±0.1 g/cm3
|
| Boiling Point |
815.5±75.0 °C at 760 mmHg
|
| Flash Point |
447.0±37.1 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.905
|
| LogP |
-1.74
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
481
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C([C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C(N)N=CN=C32)O1)OP(=O)(O)O)O)O
|
| InChi Key |
UQRXDDDXDPEXNS-VQFZJOCSSA-N
|
| InChi Code |
InChI=1S/2C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(17)7(4(1-16)21-10)22-23(18,19)2011-8-5-9(13-2-12-8)15(3-14-5)10-7(22-23(18,19)20)6(17)4(1-16)21-10/h2*2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/t2*4-,6-,7-,10-/m11/s1
|
| Chemical Name |
(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl dihydrogen phosphate compound with (2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl dihydrogen phosphate
|
| Synonyms |
Adenosine 2′(3′)-monophosphate mixed isomers 2'-Adenylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~180.00 mM)
H2O : ~50 mg/mL (~144.00 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8800 mL | 14.4001 mL | 28.8002 mL | |
| 5 mM | 0.5760 mL | 2.8800 mL | 5.7600 mL | |
| 10 mM | 0.2880 mL | 1.4400 mL | 2.8800 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02318043 | COMPLETED | Drug: inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg) |
Asthma | Guangzhou Institute of Respiratory Disease | 2007-01 | Not Applicable |
| NCT00970190 | COMPLETED | Sinusitis | Greg Davis | 2009-08 | ||
| NCT02391519 | RECRUITING | Procedure: Collection of myometrial, cord blood, and placental tissue samples |
IUGR Preeclampsia Pregnancy |
University of Colorado, Denver | 2016-01 | |
| NCT01581736 | TERMINATED | Drug: U100 Humulin Other: Exercise |
Obesity Type 2 Diabetes Mellitus |
Mayo Clinic | 2012-04 | Phase 1 |
| NCT05032729 | COMPLETED | Other: Trypophan, Theanine and 5'AMP Other: Placebo |
Balance Cognitive Performance Physical Performance Sleep |
PepsiCo Global R&D | 2022-03-14 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
